Comparison of the Effects of Empagliflozin and Sotagliflozin on a Zebrafish Diabetic Heart Failure with Reduced Ejection Fraction Model
Abstract
Abstract The sodium-glucose co-transporter 2 (SGLT2) inhibitor, empagliflozin (EMPA), and dual SGLT1/2 inhibitor, sotagliflozin (SOTA) are emerging as heart failure (HF) medications beyond their glucose-lowering-effects in diabetes mellitus (DM). However, the precise mechanism underlying this cardioprotective effect has not yet been elucidated. Here, we evaluated the effects of EMPA and SOTA in a DM combined with HF with reduced ejection fraction (DM-HFrEF) zebrafish model. The myocardial contractile functions and motility were evaluated by MicroZebraLab and DanioVision, respectively. The structural binding and modulating effect of the two medications on sodium-hydrogen exchanger 1 (NHE1) was evaluatedin silicoandin vitro. DM-HFrEF zebrafish showed impaired cardiac contractility and decreased motility and survival, all of which were improved by 5 µM EMPA or SOTA treatment. However, the 25 µM SOTA treatment group had worse survival rates and less motility preservation than the EMPA treatment group with the same concentration, and an epicardial edema and uninflated swim bladder were observed. We evaluated the structural binding and modulation effect of the two medications on NHE1 bothin silicoandin vitro. The SOTA, EMPA and cariporide (CARI) showed a similar structural binding affinity to NHE1. In addition, EMPA, SOTA, and CARI effectively reduced intracellular H+, Na+and Ca2+changes through the inhibition of NHE1 activity. These findings suggest that both EMPA and SOTA exert…
How strong is the evidence?
Evidence Hub reads this as a preprint, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.